Audentes Therapeutics, Inc., a San Francisco, CA-based biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, closed a $30m Series A financing.
The round was led by OrbiMed Advisors with participation from 5AM Ventures and Versant Ventures.
Founded in November 2012 and led by Matthew R. Patterson, President and Chief Executive Officer, in collaboration with Thomas J. Schuetz, M.D., Ph.D. and OrbiMed Advisors, Audentes is committed to the development and commercialization of new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology.
The company intends to use the funds to further advance its two lead programs, AT001 for X-linked Myotubular Myopathy (XLMTM) and AT002 for Pompe disease, and to evaluate additional candidate programs.
FinSMEs
18/07/2013